Barclays
KITE

Barclays’s Kite Pharma, Inc. KITE Stock Holding History

Barclays’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2,700
Closed -$485K – 7352
2017
Q3 		$485K Sell
2,700
-109,200
-98% -$15.2M ﹤0.01% 3660
2017
Q2 		$11.6M Sell
111,900
-123,600
-52% -$10.1M 0.01% 886
2017
Q1 		$18.5M Buy
235,500
+235,100
+58,775% +$14.5M 0.02% 587
2016
Q4 		$18K Sell
400
-119,600
-100% -$5.87M ﹤0.01% 5692
2016
Q3 		$6.7M Buy
+120,000
New +$6.69M 0.01% 1089

Barclays's KITE Position: Q4 2017 in Review

Barclays sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 48,607 shares — an estimated $8.74M sold.

Barclays first reported a position in KITE in Q4 2014 and held it in 11 quarters. The position peaked at $8.74M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.

  • Barclays reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
  • Barclays sold 48,607 Kite Pharma, Inc. shares in Q4 2017, an estimated $8.74M.
  • Barclays first reported a position in Kite Pharma, Inc. in Q4 2014 and held it in 11 quarters.
  • Barclays's Kite Pharma, Inc. position peaked at $8.74M in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.

Based on Barclays's 13F filing for Q4 2017, filed 14 Feb 2018.